Carboplatin

Generic Name: Carboplatin

Brand Names: Paraplatin

Drug Type: Small Molecule

Chemical Formula: C_₆H_₁₂N_₂O_₄Pt

CAS Number: 41575-94-4

Unique Ingredient Identifier: BG3F62OND5

Background: Carboplatin is an organoplatinum antineoplastic alkylating agent used in the treatment of advanced ovarian carcinoma. Early clinical studies of carboplatin were performed in 1982. Carboplatin was developed as an analog of cisplatin with reduced nephrotoxicity and vomiting.

Carboplatin was granted FDA approval on 3 March 1989.

Indication: Carboplatin is indicated in combination with an established combination of chemotherapeutic agents for the initial treatment of advanced ovarian carcinoma. Carboplatin is also indicated for the palliative treatment of ovarian carcinoma, recurrent after prior chemotherapy.

Associated Conditions: Advanced Cervical Cancer, Advanced Endometrial Cancer, Advanced Esophageal Cancers, Advanced Head and Neck Cancer, Advanced Melanoma, Advanced Non-Small Cell Lung Cancer (NSCLC), Advanced Ovarian Carcinoma, Advanced Sarcoma, Malignant Pleural Mesothelioma (MPM), Merkel Cell Carcinoma, Metastatic Breast Cancer, Refractory Hodgkin Lymphoma, Retinoblastoma, Thymoma, Advanced Bladder cancer, Advanced Small cell lung cancer, Advanced Testicular cancer, Advanced Thymoma, Refractory Non-Hodgkin's lymphoma

Associated Therapies: Conditioning regimens for allogeneic stem cell transplantation therapy

Clinical Trials

Pemetrexed Disodium and Carboplatin in Treating Patients With Extensive-Stage Small Cell Lung Cancer

Phase 2

Completed

Conditions: Lung Cancer

Interventions: Drug: carboplatin
Drug: pemetrexed disodium
Radiation: radiation

First Posted Date: 2005-09-28

Last Posted Date: 2016-07-06

Lead Sponsor: Alliance for Clinical Trials in Oncology

Target Recruit Count: 50

Registration Number: NCT00227565

Locations: 🇺🇸
Hennepin County Medical Center - Minneapolis, Minneapolis, Minnesota, United States
🇺🇸
St. Mary - Corwin Regional Medical Center, Pueblo, Colorado, United States
🇺🇸
Rush-Copley Cancer Care Center, Aurora, Illinois, United States

and more 145 locations

Treatment of Newly Diagnosed Ovarian Cancer With Antioxidants

Phase 1

Completed

Conditions: Ovarian Cancer

Interventions: Dietary Supplement: Oral Ascorbic Acid
Drug: Paclitaxel
Drug: Carboplatin
Drug: Sodium Ascorbate
Dietary Supplement: Oral Mixed natural Carotenoids with Vitamin A
Dietary Supplement: Vitamin E

First Posted Date: 2005-09-28

Last Posted Date: 2018-06-19

Lead Sponsor: Jeanne Drisko, MD, CNS, FACN

Target Recruit Count: 27

Registration Number: NCT00228319

Locations: 🇺🇸
University of Kansas Medical Center, Kansas City, Kansas, United States

Induction Gemcitabine & Carboplatin Followed by Paclitaxel & Carboplatin +XRT in NSCLC

Phase 2

Completed

Conditions: Lung Cancer

Interventions: Drug: Gemcitabine
Drug: Carboplatin
Drug: Paclitaxel
Procedure: Radiation

First Posted Date: 2005-09-27

Last Posted Date: 2017-03-23

Lead Sponsor: H. Lee Moffitt Cancer Center and Research Institute

Target Recruit Count: 39

Registration Number: NCT00226590

Locations: 🇺🇸
H. Lee Moffitt Cancer Center & Research Insitute, Tampa, Florida, United States

Docetaxel and Carboplatin in Treating Patients With Relapsed Stage III or Stage IV Ovarian Epithelial or Primary Peritoneal Cavity Cancer

Phase 2

Completed

Conditions: Ovarian Cancer
Peritoneal Cavity Cancer

First Posted Date: 2005-09-22

Last Posted Date: 2010-09-21

Lead Sponsor: Fred Hutchinson Cancer Center

Registration Number: NCT00217568

Locations: 🇺🇸
University of Washington School of Medicine, Seattle, Washington, United States
🇺🇸
Pacific Gynecology Specialists, Seattle, Washington, United States
🇺🇸
Fred Hutchinson Cancer Research Center, Seattle, Washington, United States

The 'MADe IT' Clinical Trial: Molecular Analyses Directed Individualized Therapy for Advanced Non-Small Cell Lung Cancer

Phase 2

Completed

Conditions: Carcinoma, Non-Small-Cell Lung

Interventions: Drug: Vinorelbine
Drug: Docetaxel
Drug: Gemcitabine
Drug: Carboplatin

First Posted Date: 2005-09-22

Last Posted Date: 2017-03-23

Lead Sponsor: H. Lee Moffitt Cancer Center and Research Institute

Target Recruit Count: 53

Registration Number: NCT00215930

Locations: 🇺🇸
H. Lee Moffitt Cancer Center & Research Institute, Tampa, Florida, United States

Erlotinib, Docetaxel, and Carboplatin in Treating Patients With Newly Diagnosed Stage III or Stage IV Ovarian Epithelial, Primary Peritoneal Cavity, or Fallopian Tube Cancer

Phase 1

Completed

Conditions: Fallopian Tube Cancer
Ovarian Cancer
Peritoneal Cavity Cancer

First Posted Date: 2005-09-22

Last Posted Date: 2010-09-21

Lead Sponsor: Fred Hutchinson Cancer Center

Registration Number: NCT00217529

Locations: 🇺🇸
Pacific Gynecology Specialists, Seattle, Washington, United States
🇺🇸
University of Washington School of Medicine, Seattle, Washington, United States
🇺🇸
Fred Hutchinson Cancer Research Center, Seattle, Washington, United States